Mumbai: Pharma major Lupin Limited (Lupin) won the Par Excellence Award at the 33rd National Convention on Quality Concept (NCQC), organised by the Quality Circle Forum of India (QCFI). The event was held at IIT BHU — Varanasi from November 26-30, 2019. Lupin’s nomination summarised its transformation project to improve the yield and quality of Cefadroxil products.
Speaking on the occasion, Rajendra B Chunodkar, President — Manufacturing Operations, Lupin said, “As a leading pharmaceutical company, we have persistently focused our efforts toward enabling manufacturing excellence at all our sites. This award endorses our approach and felicitates our efforts toward quality and continuous improvement.”
Twice in short succession, Lupin’s Ankleshwar facility received recognition for its “Cefadroxil Yield and Quality Improvement” project. In the previous instance, the facility won the gold award by the American Society for Quality at the Annual Conference on Quality Management in Ahmedabad.
QCFI is recognized as the institution representing The Quality Circle Movement in India and has represented the country in several international forums. The organization has successfully implemented Quality concepts under the TQM umbrella across several industry verticals which have experienced a phenomenal enhancement of their work processes and productivity after implementation of Quality Concept Tools. QCFI represents India in the 14 nation International Committee that has been set up for organizing international conventions on Quality Concept Circle, annually. To date, QCFI has organized three International convention in India.
About Lupin Limited
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
Lupin is the 8th largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3rd largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2019).
For the financial year ended March 31, 2019, Lupin’s Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on LinkedIn and Facebook at https://www.linkedin.com/company/lupinglobal/ and https://www.facebook.com/LupinWorld/ respectively.
CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055
For further information or queries please contact:
Head – Investor Relations and M&A / Corporate Communication